Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]yohimbine + clonidine is a research-grade combination used in positron emission tomography (PET) imaging studies, specifically those conducted by Hospices Civils de Lyon. The combination consists of [11C]yohimbine, a radiolabeled small molecule that acts as an antagonist for alpha-2 adrenergic receptors, and clonidine, a well-characterized alpha-2 adrenergic receptor agonist. In this experimental setup, [11C]yohimbine serves as the imaging tracer to visualize receptor distribution in the brain, while clonidine is administered to displace the tracer from the receptors. This pharmacological challenge allows researchers to quantify receptor occupancy and validate the kinetic modeling of the tracer, facilitating the study of the alpha-2 adrenergic system in humans.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C]yohimbine + clonidine.